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from the editors. . .
As your co-Presidents for The William H.
Beaumont Medical Research Honor Society, we
are proud to present you with the fourth edition
of Fusion, GW School of Medicine and Health
Science’s (SMHS) entirely student-run research
journal, featuring basic science, clinical, and
health policy research conducted by GW medical
students. The articles span a wide variety of
clinical specialties and scientific disciplines, from
genetics and orthopaedic surgery to neurosurgery
to cardiology to cancer research and therapy. This
year we limited submissions to student research
conducted during medical school that led to
quantifiable scientific results, which we believe
enhances the quality of Fusion as a student scientific journal and as a reflection of the significant
research accomplishments of GW medical students. This is an exciting time to be conducting
research at SMHS — with GW Medical Center
(GWUMC) receiving major grants such as the
Department of Microbiology, Immunology and
Tropical Medicine’s recent $15 million grant from
National Institutes of Health (NIH) — and we
are excited to be representing student research at
SMHS through the Beaumont Society.
We are pleased to have continued our Journal
Club meetings this year, and have improved the
format of Journal Club by taking advantage of
a rich resource immediately at our fingertips —
recruiting leading faculty members and specialists
in their fields to moderate our discussions, providing valuable clinical and seasoned perspectives
on key topics. Stay tuned for more discussions of
current research articles this spring, led by our
M.S.I Beaumont members!
One frequently asked question is, “What
is Beaumont anyway?” The standard answer
is that Beaumont is a student-run society for
students with an enthusiasm for, and an interest
in, research. We provide students with a forum
to discuss current and past landmark scientific
studies through our Journal Club, an outlet to
share their research findings with their peers and
the GWUMC community through publication
in Fusion and poster presentations at Research
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Day, and a resource to learn about research
opportunities available at GW, the NIH, and
across the United States. The real answer, however, is that Beaumont is whatever you want it to
be — we are always open to new ideas and suggestions and we invite you to submit yours to us
at gwbeaumont@gmail.com.
We would like to give our special thanks to
Dean James Scott, M.D.; Dean Scott Schroth,
M.D.; and Associate Vice President Anne
Hirshfield, Ph.D., for their dedicated guidance
and support as well as their innovative suggestions for the improvement of the Beaumont
Society, to our past (and future) Journal Club
faculty moderators, Lakhmir Chawla, M.D., and
Lisa Martin, M.D., as well as all of the faculty
who mentored our peers during their research
projects, as well as to Thomas Kohout for his
hard work, patience, and positive attitude while
assembling this year’s journal and the student
authors and the editors of Fusion for all of their
hard work throughout the editing process. Our
final thanks go to Beaumont Society VicePresident and fellow Fusion Editor-in-Chief,
Sonia Samtani, for her work ethic, enthusiasm
and spirit during this entire process.
Thank you all and we hope you, the
GWUMC community, enjoys Research Day and
Fusion 2010!

Kate M. Serdy, M.S.II

Allison B. Spitzer, M.S.II

Sincerely,
Kate Serdy, M.S.II

Allison Spitzer, M.S.II

Co-Presidents of the William Beaumont Society
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from the dean’s office. . .
Congratulations to the students
of The George Washington
University on the research
featured in this fourth edition
of Fusion. A special thanks to
Allison Spitzer, Kate Pickoff
and Sonia Samtani as well
as the rest of the William H.
Beaumont Medical Research
Honor Society for all of your
hard work to make this journal
possible. I would also like
to recognize Dr. Anne N.
Hirshfield who serves as the
faculty advisor to the Beaumont
Society for the encouragement she gives to our students
working in research. I would
also acknowledge the importance of the enthusiasm and dedication of our scientific investigators. Finally, I’d like to acknowledge the staff
in the Office of Student Opportunities and the
generous supporters of that office who continue
to make medical research attainable for many of
our students.
In every way research is growing at the GW
School of Medicine and Health Sciences and
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Children’s National Medical Center. We have
major new grants in cancer, quality outcomes,
neuroscience and tropical diseases. Our residents
have presented and published more papers than
ever and there are a myriad of opportunities for
research activities by students. Scientific discovery and the creation of new knowledge is the
hallmark of any School of Medicine and Health
Science and with this publication we recognize
the vital and stimulating role that our students
have in our research accomplishments.
Fusion is a student-run publication that
showcases the abilities of the students of the
School of Medicine and Health Sciences. I take
great pride in the achievements of our students
and hope you are as impressed with their work
as I am.

James L. Scott, M.D.
Dean, School of Medicine and Health Sciences,
Professor of Emergency Medicine
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from the research office. . .
In collaboration with the students of GW’s
William Beaumont Medical Research Honor
Society, I am proud to present the 2010 edition
of Fusion, the fourth volume of a publication
created by the members of this prestigious honor
society. The William H. Beaumont Medical
Research Honor Society was established at the
GW School of Medicine in 1935 to promote
student research.
The officers of the Society wanted to communicate the excitement and value of their
experiences to you while carrying out research
rotations, summer projects and activities that are
preparing them for their medical careers. The
previous editions of Fusion have been received
with enthusiasm and, as a result, you, the wider
audience have reaped the benefits from perusing
the pages of this journal.
Fusion is an entirely student run publication
that highlights the students’ abilities as promising doctors and researchers. In addition, we
salute the faculty advisors and all those who have
mentored and assisted in any way to make this
publication a reality. We also need to acknowledge the W.T. Gill Endowment, which on a
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yearly basis, provides stipends
to eligible students to gain
valuable experience in research
during the summer months.
As our health care system
evolves and as new discoveries
in medicine become evident,
our students’ efforts now will
prepare them for the challenges that lie ahead. I am
honored to serve as the society’s faculty advisor and am
happy to support these gifted
students in their research
endeavors.

Anne N. Hirshfield, Ph.D.
Associate Vice President for Health Research
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Basic Science. . .
RNA Interference in Virus Induced Hepatitis C and
the Silencing Mechanism of Tumor Suppressing Genes

Kulin Shah, M.S.I
Research Track,
Advisor: Ajit Kumar, Ph.D.,
Professor of Biochemistry and
Molecular Biology,
The George Washington
University School of Medicine
and Health Sciences,
Washington, DC.
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Hepatitis C, caused by the Hepatitis C Virus
(HCV), is an infectious disease affecting the
liver. Although asymptomatic upon acute
infection, chronic infection can lead to liver
cirrhosis and potential liver failure.1 With
no vaccine currently available, an estimated
170 million people are chronically infected
worldwide with 3–4 million people becoming
newly infected each year.2
Upon infection, HCV induces precursor
microRNA (miRNA) to develop into mature
miRNA by interaction with the DICER
protein, an endoribonuclease that cleaves premiRNA into short, miRNA fragments. The
mature miRNA, a double-stranded RNA
molecule of 21–23 nucleotides, interacts with
Ago proteins which initiate the selection of the
complementary guide strand and catalyze its
binding to target mRNA of hepatocyte tumor
suppressor genes (TSGs).3 This multiprotein
complex of Ago proteins and miRNA is known
as a RNA-induced silencing complex (RISC).4
RISC disrupts the tumor suppressor genes’
level of expression via translational function
repression.5 The down regulation of TSGs leads
to the uncontrolled growth of hepatocytes and
subsequent hepatocellular cirrhosis and potential
carcinoma. However, it is unclear exactly where
and how RISC is formed within the cell as well
as how the activated complex locates the mRNA
targets.
RNA binding proteins TRBP and HuR are
integral components in the formation of RISC.
More specifically, these proteins are involved in
the recruitment of other proteins such as Ago to
the pre-miRNA/dicer complex.5 The purpose of
our study was to discover the cellular localization
of where these proteins originate and function
within HCV infected cells. Such knowledge
would provide us with more insight as to where
RISC is formed and the mechanisms by which it
interferes with gene expression.
Wild type hepatocytes (used as standards)
and mutant hepatocytes infected with HCV were

grown separately and subsequently transfected
with FLAG-tag TRBP and HuR proteins to
increase their relative intracellular concentrations.
Following incubation, a cellular fractionation
separated the cytoplasmic, nuclear, and nucleolar
components of the cells. A western blot using
an anti-FLAG antibody was performed to assess
the location in which normal and mutant cells
were using TRBP and HuR for their biochemical
processes. Following several trials, our results
indicated that in both wild type and HCV
infected cells, varying HuR concentrations were
found throughout the cellular compartments.
However, higher TRBP concentrations were
encountered in the nucleolus of infected
cells when compared to normal cells. Our
hypothesis of RNA binding proteins, specifically
TRBP, demonstrating increased activity in
specific regions of the cell during infection
was substantiated. The variability in HuR,
however, highlights the complexity of culturing,
transfecting, and fractionating viable hepatocytes.
Procedural and analytical modifications to
achieve reproducible results are currently being
developed. Nevertheless, the preliminary results
of this project suggest that TRBP resides mainly
in the nucleolus upon infection and therefore,
RISC formation and interference may occur in
proximal vicinity. However, more research is
needed to determine the roles these proteins play
in RNA interference and the cellular regions
they are most active in. Such information can
help elucidate the complex biochemical processes
involved in advancing Hepatitis C infection
from an acute to chronic stage. Moreover, by
understanding the specific interactions between
proteins along the gene silencing cascade, steps
can potentially be targeted and therapeutically
knocked down to disrupt disease progression.

REFERENCES:
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Ethanol-Induced Apoptosis in Cultured Cells
is Mediated by the Endoplasmic Reticulum
Alcohol abuse, known for promoting cell death
in the liver and nervous system, is a major public
health concern.1–2 Despite significant morbidity
and mortality resulting from alcohol, its precise
cellular mechanism remains unknown. The
present study investigated the sub-cellular
mechanism of ethanol toxicity, specifically
whether ethanol-induced apoptosis involves the
mitochondria or endoplasmic reticulum (ER).
Ethanol induces apoptosis in cells via a
caspase-dependent mechanism.3 Control of
caspase activity, and thus apoptosis, is directly
modulated by the Bcl-2 family of proteins,
which includes both pro- and anti-apoptotic
members.4 Anti-apoptotic Bcl-2 protects
cells from apoptosis by inhibiting caspase
activation, and Bcl-2 is known to be localized to
mitochondria and the ER.5 Prior in vivo studies
have shown that overexpression of wildtype Bcl-2
is protective against ethanol toxicity,but it is not
known whether protection is mediated through
mitochondrial Bcl-2 or ER Bcl-2.6
Chinese hamster ovary cells (CHO695) were
transiently transfected with cDNA constructs
encoding GFP:Bcl-2 wildtype, GFP:Bcl-2
MAOB (mitochondria targeted) or GFP:Bcl-2
Cb5 (ER targeted) in order to determine the
subcellular mechanism of rescue from ethanol
toxicity by Bcl-2. MTT assay was used to
measure cell viability in response to a range of
ethanol concentrations at different time points
in naïve CHO695 cells or in CHO695 cells
overexpressing wildtype or organelle-targeted
Bcl-2. Cells expressing GFP alone served as
control. Ethanol treatments of 1 M and 2.5
M caused significant cell death at five, 10 and
24 hours. Wildtype Bcl-2 provided significant
rescue for CHO695 cells treated with 1 M
ethanol at the most severe (24 hour) time
point, but did not rescue from toxicity at 2.5 M
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ethanol. However, ER-targeted Bcl-2 provided
significant and robust rescue at 1 M and 2.5 M.
Interestingly, mitochondrial-targeted Bcl-2
offered no significant protection at any ethanol
concentration, suggesting the ER is central to the
ethanol apoptosis mechanism.
In order to confirm these transfection data,
and determine the sub-cellular mechanism
of rescue from ethanol toxicity, we employed
a peptide inhibitor approach to investigate
whether mitochondria or ER caspases were
responsible for ethanol-induced apoptosis.
Caspase-9 and caspase-12 are known to be
downstream of mitochondria and endoplasmic
reticulum, respectively. CHO695 cells were
treated with either a pan-caspase inhibitor, a
caspase-9 inhibitor or a caspase-12 inhibitor
and then treated with 1.5 M ethanol. MTT cell
viability assay was used to measure cell viability
in response to ethanol treatment. Untreated
cells served as a control. Treatment with the
pan-caspase inhibitor provided significant rescue
from ethanol toxicity. Inhibition of caspase-12
conferred significant protection from ethanol
toxicity as well, while inhibition of caspase-9 did
not provide significant rescue. These findings
confirm our transfection data and demonstrate a
central role for the ER in ethanol toxicity.
In conclusion, the present study indicates
that Bcl-2’s amelioration of ethanol toxicity is
most likely mediated through the ER. Therefore,
ethanol-induced apoptosis does not occur via
a mitochondrial stress pathway and caspase-9
activation but rather through an ER stress
pathway and subsequent caspase-12 activation.
Future work should clarify the role of the ER in
ethanol toxicity.

APOPTOSIS

Andreea Balan, M.S.III
Advisor: D. Blaine Moore, Ph.D.,
Associate Professor of Biology,
Kalamazoo College,
Kalamazoo, MI.

Continued on p. 8
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Fibroblast Growth Factor Receptor (FGFR)
Trafficking is Modulated by Shisa

Kate M. Serdy, M.S.II
Research Track
Advisor: R. Cartland Burns,
M.D., Associate Professor of
Surgery, University of Pittsburgh
Medical Center, Pittsburgh, PA.

FIGURE 1: The top three

images confirm expression of
mShisa in the ER.The bottom
three images confirm that
mShisa is also present in the
Golgi complex.
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The requirement for mesenchymal fibroblast
growth factor 10 (FGF10) signaling in gastrointestinal development has been previously demonstrated. Through epithelial FGF receptor 2-IIIb
(FGFR2b), a tyrosine kinase transmembrane
receptor, FGF10 facilitates the epithelial-mesenchymal interaction and is necessary for proper
development of the gut from embryonic days
E11.5-E15.5 in mice. This mechanism is exhibited in FGF10 or FGFR2b null mice that demonstrate intestinal atresia in similar phenotypes.
Defining the means by which the expression of
FGF10 or FGFR2b are regulated may contribute
to a more complete
understanding of
the development of
intestinal atresia.
Before cell
surface expression,
FGFR2b must
undergo posttranslational
glycosylation. This
modification occurs
in the Golgi complex
after the receptor
is released from
the endoplasmic
reticulum (ER).
Shisa is an ER
retention molecule
that is known to

bind with FGFR2b, and it has been postulated
that Shisa may modulate the membrane
availability of FGFR2b by regulating the
movement of the receptor from the ER to the
Golgi complex for glycosylation. Shisa is known
to bind with FGFR2b in the ER, but it has not
been shown to be present in the Golgi complex.
To demonstrate Shisa expression, HeLa
cells were transfected with mShisa-GFP and
mCherry-ER (as an ER marker). Confocal
microscopy was used to evaluate co-localization.
Immunostaining was performed with affinitypurified cation-independent mannose-6-
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phosphate receptor (CI-M6PR) as a Golgi
marker, and, co-localization was identified by
confocal microscopy. The top three images of
Figure 1 confirm expression of mShisa in the ER.
The bottom three images confirm that mShisa is
also present in the Golgi complex.
These data demonstrate the presence of
Shisa in both the ER and Golgi complex,
supporting a potential role for Shisa in the
regulation of FGFR2b maturation and therefore
its cell surface availability. Alterations in Shisa
expression during gut development may be
a contributing factor to the development of
intestinal atresia phenotypes in which the lack of
FGF10/FGFR2b signaling has been implicated.

REFERENCES:
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BURNS RC, ET AL. Requirement for fibroblast growth

factor 10 or fibroblast growth factor receptor 2-IIIb
signaling for cecal development in mouse. Developmental Biology. 2004; 265:61–74
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NAGANO T, ET AL. Shisa2 promotes the maturation of
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299:373–385.

Macrophage Targeted Photodynamic Therapy
of Inflammatory Atherosclerosis
Cardiovascular disease complications such as
myocardial infarction and stroke are leading
causes of death worldwide.1 Atherosclerosis is
an inflammatory vascular disease initiated by
lipid deposition into the subendothelial space.
Oxidation of retained lipids induces a sustained
inflammatory response, recruiting monocytes to
the site of injury. Monocytes differentiate into
macrophages in an attempt to scavenge oxidized
lipids. Unable to regress from the vascular wall,
retained macrophages secrete pro-inflammatory
and growth factors. Thus, the macrophage is
critically involved in atheroma expansion and
fibrous cap destabilization. Unstable fibrous
caps can rupture, leading to thrombosis
and consequent myocardial infarction or
stroke.2, 3 Early identification and treatment of
macrophage-rich plaques can significantly limit
the morbidity due to atherosclerosis.
Directed therapy of inflamed atherosclerotic
lesions is an approach to limit consequences
of vascular disease. This study investigated
integrated fluorescent imaging and
photodynamic therapy (PDT) nanotechnology
to ablate inflammatory macrophages, a wellestablished therapeutic target for atherosclerosis.4
This strategy aims to stabilize inflamed,
macrophage-rich atherosclerotic plaques.5–7
PDT involves injectable photosensitizers
and subsequent light illumination to induce
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cytotoxic singlet oxygen formation and apoptosis of diseased cells. Since photosensitizers are
light-activated, PDT can be selectively applied,
potentially reducing risk of systemic toxicity.
Current clinical photosensitizers (i.e. chlorin)
lack specific avidity for inflammatory cells within
atherosclerotic lesions. To address this issue, our
laboratory developed a macrophage-targeted
nanoparticle (CLIO, cross-linked iron oxide)
conjugated to a photosensitizer that targets
plaque macrophages.5,8,9
An in vitro assay was developed to assess
PDT uptake and efficacy in murine macrophagetype cells (RAW264.7) and compare the efficacy
of CLIO-GPC (a new, more chemically efficient
photosensitizer) to conventional photosensitizers
and control nanoparticles.10 Two sets of cells were
incubated with CLIO-GPC or chlorin at 37ºC
for 90 minutes. One set of cells then underwent
laser illumination for 5 minutes at 100 milliWatts power while the other set remained in the
dark. After 24 hours, cell viability was quantified using the MTS assay to measure magnitude
of cell death. The second part of this project
repeated the same procedures on primary peritoneal murine macrophages to gauge dosing and
potency of the agent before moving to pure in
vivo models for testing.

Neha Jakhete, M.S.II
Research Track
Advisor: Farouc Jaffer, M.D.,
Ph.D., Assistant Professor of
Medicine, Harvard Medical
School Cardiology Division,
Cardiovascular Research
Center, and Center for
Molecular Imaging Research,
Massachusetts General Hospital,
Boston, MA.
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CLIO-GPC did not induce RAW cell
killing as hypothesized. Free chlorin and
CLIO-chlorin were more potent inducers of
apoptosis (1 percent viability at 20 uM chlorin,
15 percent viability at 5uM chlorin) than GPC
or CLIO-GPC. Fluorescent imaging found free
GPC to be taken up more readily by RAW cells
than GPC conjugated to CLIO, though no cell
death was seen upon illumination. However,
promising results were seen in primary peritoneal
macrophages. While CLIO-GPC did not
produce cell death, we did see
cell death with free
GPC.

atherosclerosis. These results may have important
implications for atherosclerotic treatment via
noninvasive (carotid artery) or catheter-based
(coronary artery) delivery of excitation light.
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Lack of cell death with GPC
could point to a problem with the
production of free oxygen radicals when
illuminated. More work needs to be done
with GPC to understand its potential as a
photosensitizer for PDT. Currently its potency
is questionable due to reduced cell uptake.
However, the CLIO-chlorin results are
promising due to both high and targeted cell
death. These in vitro results have motivated an in
vivo study evaluating the ability of CLIO-chlorin
to ablate plaque macrophages in experimental
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clinical practice. . .
Dynamic Stabilization for the Treatment
of Degenerative Spinal Disorders
The field of spine
surgery has been
revolutionized by
advances in technology. Many of
these technologies
improve existing
techniques while
others introduce
new instruments,
procedures, and
approaches to
degenerative
spinal pathology.
Historically, spinal
fusion has been the
gold standard for degenerative spine disease.1
However, spinal fusion eliminates vertebral
motion and places greater mechanical stress
on adjacent spinal segments.2 3 As an alternative, motion-preserving technology, such as
the Dynesys Dynamic Stabilization system has
emerged. This device is implanted with pedicle
screws over the posterior spine, allowing motion
at the affected joint location, whereas standard
fusion eliminates it. Dynamic stabilization was
recently applied at our institution for select
patients. This project presents the pre-operative
and post-operative outcomes of this device.
In this study, we reviewed charts for consecutive patients who received the Dynesys
Dynamic Stabilization system for the treatment
of degenerative spinal disorders. This retrospective review followed 17 patients for an average
of 5.3 months. Questionnaires completed preoperatively and at each post-operative follow-up
clinical exam assessed the patients’ quality of life
and current pain levels.
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Based on the
Oswestry Low Back
Pain and Disability
Scale, patients
receiving Dynesys
Posterior Dynamic
Stabilization had a
48 percent reduction
in pain levels from
their pre-operative
state. To measure
specific regions
of pain, we used
the Visual Analog
Scale. Based on this
measure, patients
reported a 42 percent improvement in leg pain
and a 55 percent improvement in back pain.
The Dynesys Dynamic Stabilization technology presents a new approach to treating
degenerative spinal disorders. It has several
biomechanical advantages over fusion and has
demonstrated clinical success in this cohort of
patients.
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Orthopaedic surgery carries a significant risk
percent, but higher than that recorded by Nicol
for developing deep vein thrombi (DVT) and
of 0.29 percent.2,5
pulmonary emboli (PE) due to the associated
The following significant risk factors for
1
bleeding and clotting. Without prophylaxis,
DVT and PE are displayed in Graph 1: active
malignancy, previous DVT/PE, ERT, discharge
43 percent of post surgical spine patients will
2
to home versus rehab, major depressive disorder
develop DVT. Pre-spinal surgery chemical
anticoagulation is contraindicated as it has
(MDD), hypertension (HTN), renal disease,
resulted in 0.2 percent incidence of epidural
congestive heart failure (CHF), and benign
hematoma significant enough to require
prostatic hypertrophy (BPH).
3,4
Analysis showed that the following were
another operation. Pneumatic compression
not significant risk factors: smoking, multiple
stockings reduce the combined DVT plus PE
incidence to 0.29 percent – 3.5 percent.2,5 The
procedures within 30 days, obesity, gender,
Transforaminal/ Posteriorforaminal Lumbar
GERD, hyperlipidemia, and sleep apnea.
Intrabody Fusion (TLIF/PLIF) surgical
Contrary to Nguyen and colleagues, relative risk
procedure has been shown
to be a risk factor for the
development of DVT and
TABLE 1: INCIDENCE OF DVT AND PE
PE.6 Our hypothesis is that
FOLLOWING MAJOR SPINAL SURGERY.
the incidence of DVT and PE
Number of surgeries analyzed for DVT/PE’s
1502
is a function of patient risk
Number of DVT counted
6
factors and co-morbidities
Number of PE counted
11
and not of the type of surgical
Number of DVT+PE
17
procedure performed (e.g.
7
TLIF/PLIF). Therefore,
Incidence of DVT
0.4 percent
the purpose of this study
Incidence of PE
0.7 percent
is to provide a large scale
Incidence of combined DVT + PE
1.1 percent
analysis of DVT and PE
surgical procedure risk,
co-morbidities, and incidence.
calculations for TLIF/PLIF surgery show no
This project determined the incidence and
risk factors of DVT and PE following major
increased risk for DVT plus PE (p = 0.8).6
spinal surgery performed by two surgeons in
As a result, the study hypothesis is not
rejected, as TLIF/PLIF surgical procedures are
the Department of Orthopaedic Surgery at The
George Washington University Hospital.
not shown to be a significant risk factor and
several patient risk factors and co-morbidities
Data were obtained by retrospective chart
review of 1,502 surgeries performed from 2001–
were shown to be significant. The cause of the
09. Datapoints recorded included procedure
difference in DVT plus PE incidence between
type, body mass index (BMI), smoking history,
Epstein, Nicol, and this study is unknown.2,5
age, medical co-morbidities, DVT prophylaxis
This study identified new risk factors: MDD,
HTN, BPH. Increasing prophylaxis measures
employed, length of stay, and any DVT risk
for patients with these co-morbidities may be
factors. For the purpose of this review, DVT
indicated. Future studies are encouraged to
risk factors were classified as previous DVT/
PE, previous or active malignancy, the use of
look at the level of prophylaxis used on patients
estrogen replacement therapy (ERT), and the
versus DVT and PE incidence. Specifically, the
relationship of DVT plus PE incidence versus
use of oral contraception. We found that the
how many hours postoperatively chemical
incidence of DVT plus PE of 1.1 percent (Table
anticoagulation is administered should be
1) was lower than that reported by Epstein of 3.5
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GRAPH 1: Significant

DVT/PE Risk factors after spinal
surgery. Factors that increase
risk are active malignancy,
previous DVT/PE, ERT, HTN,
MDD, renal disease, CHF, and
BPH. Discharging the patient to
home, versus rehab, decreases
risk.

Exposure of the Spine for Removal of Lumbar

Outcomes of Patellar Realignment
for Patellofemoral Arthritis in Young Patients
One of the most common symptoms of people
seeking treatment from orthopedic surgeons is
anterior knee pain associated with patellofemoral
arthritis.1 Conservative methods to alleviate
symptoms of patellofemoral arthritis, including
physical therapy, bracing, or hyaluronic acid
injections, can help relieve some of the mechanical symptoms, pain, and swelling, but relief is
often temporary.1–5 If conservative methods fail,
there are a variety of surgical interventions for
treatment of patellar pain and instability, but
few target patellofemoral arthritis specifically.1–4
Selecting the best operative method depends on
patient age, activity level, the severity and the
location of the chondral damage.2,3
Patellar realignment consisting of tibial
turbercle osteotomy with anterior and medial
transfer of the tibial tubercle (Figure 1) was
originally described in 1983 by J.P. Fulkerson et
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al.7,8 Transferring the tibial tubercle anteriorly and
medially aims to maintain the extensor mechanism and shift the load off of the painful, degenerated area of cartilage.3–7 Previous studies using
tibial tubercle anteromedialization procedures
have described good results for the treatment of
patellar instability and, more recently, for the
treatment of patellofemoral arthritis in the adult
population above 50 years old.1,3,4,6,8–10
However, the success of patellar realignment
for the treatment of patellofemoral arthritis
remains largely unknown, especially in the
younger population where maintaining functional ability is of primary importance.9 The
objective of this study was to determine the
effectiveness of patellar realignment through
tibial tubercle anteromedialization in treating

PATELLAR REALIGNMENT

Meghan Bishop, M.S.II
Advisor: Robin V. West, M.D.,
Associate Professor of
Orthopaedic Surgery,
University of Pittsburgh
Medical Center, Pittsburgh, PA.
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PATELLAR REALIGNMENT Continued from p. 13
localized patellofemoral arthritis in patients under
of 42 years of age.
Between October 2003 and October 2007,
the tibial tubercle anteromedialization procedure
was performed on 24
knees (18 patients) by a
FIGURE 1. Postoperative AP and lateral radiographs
single surgeon (R.V.W.)
demonstrating the position of the patella, tubercle, and
for the treatment of
hardware.
localized patellofemoral
arthritis. Results were
retrospectively reviewed
at a mean 3.6 years after
surgery. Correlations
between age, length
of follow-up, degree
of chondral damage,
and mean BMI were
made with the IKDC
Subjective Knee
Evaluation Form score
evaluated at follow-up.
Patients’ charts and
preoperative radiographs
were reviewed in order
to correlate physical exam and pre-operative
radiographic measurements with the final results
(Figure 2). Outcomes were determined using
standard physical examination modalities, the
FIGURE 2. Preoperative and postoperative Merchant
IKDC Subjective Knee
radiographs demonstrating realignment of the patella.
Evaluation Form, and
patient-directed questions regarding satisfaction with the surgery.
Patellar realignment
was performed on 24
knees (18 patients).
There were fourteen
women and four men
with a mean age of 27.8
years and a BMI of 29.6.
The mean IKDC score
was 72.8 at an average
length of follow-up of
3.6 years. The IKDC
score was not significantly associated with
age, length of follow-up, BMI, congruence angle,
patellar height, or grade of chondrosis. All but

14

two patients (three knees) reported to be greatly
or somewhat improved by the surgery and all
but two patients (two knees) would undergo the
surgery again.
This data suggests that patellar realignment
can be performed in properly selected young
patients with localized patellofemoral arthritis
and can result in good outcomes. Although
patient IKDC scores do not meet the normative
IKDC scores for the age and gender matched
population, the majority of patients felt that their
condition was greatly improved with the surgery
and would opt to have the surgery again. Patellar
realignment through tibial tubercle anteromedialization should be considered as a good option
in treating patellofemoral arthritis in the young
population when conservative treatments have
failed to provide relief from pain.
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Volumetric Analysis Reveals White Matter Volume Loss in Adults
with Partial Ornithine Transcarbamylase Deficiency (OTCD)
The urea-cycle disorders (UCDs) are a rare
group of inborn errors of metabolism that result
in failure to convert ammonia to urea, leading
to hyperammonemia and substantial cognitive
and motor deficits. Ornithine Transcarbamylase
Deficiency (OTCD) is the most common UCD,
with symptoms of protein intolerance and deficits
in executive functioning, working memory, and
motor planning. As
ammonia crosses the
blood-brain barrier,
it becomes trapped
in the brain. In order
to buffer excess
ammonia, astrocytes
combine glutamate
with ammonia to
form glutamine via
the enzyme glutamine synthetase.
Glutamine is not as
toxic as ammonia,
but is osmotically
active in astrocytes;
excess glutamine
results in astrocyte
swelling, which can lead to cerebral edema,
increased intracranial pressure, or coma. This
mechanism is thought to explain the white matter
damage associated with hyperammonemia,but
there have been no quantitative measures of white
matter volume in this disorder.1
The purpose of this study was to quantitate
white matter volume (WMV) in OTCD patients
by using a voxel-based morphometry (VBM)
approach. VBM is a neuroimaging analysis technique that allows comparison of the local concentration of matter between groups of subjects,
and it involves normalizing the images into the
same stereotactic space.2 The hypothesis was that
decreased WMV would be observed.
High-resolution 3D MRI data were acquired
from 22 adult patients with partial OTCD and
22 healthy age-matched volunteers without
neurological impairment (Figure 1). The subject
group included late onset males with OTCD
as well as both asymptomatic and symptomatic
females heterozygous for OTCD, with varying
ages of diagnosis and metabolic control. VBM
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was performed on a PC using Matlab 7.4 and
SPM5 software.
VBM analysis showed that OTCD patients
have less white matter volume than age matched
controls (p < 0.0385 False Discovery Rate).
Depicted are the results of a two-way-t-test
showing differences in white matter volumes. The
colors indicate areas of decreased volume on an
intensity scale.
There was damage to
FIGURE 1:
the anterior limb of the
Cross hair marks
internal capsule and the
WM loss of internal
superior corona radiata.
capsule.
These two connected
white matter sheets are
Cross hair marks
important for communiWM loss of superior
cation between the cortex
corona radiata.
and subcortical structures;
Cross hair marks WM information flows from
the thalamus through
loss of cerebellum.
the internal capsule and
corona radiata until it
WM loss of diffuse
reaches the cortex. The
areas of frontal
corona radiata coalesces
cortex.
on to the centrum semiovale, the white matter
core of the cerebral hemispheres that has been
shown to be damaged in previous studies on
OTCD.3 There was also white matter loss in the
cerebellum (p <0.0385), an area known for its role
in coordination and motor control. This could
explain the common symptom of decreased fine
motor control found in typical OTCD patients.
There was diffuse white matter loss in the frontal
cortex, the area of the brain responsible for executive function, which could explain the cognitive
deficits seen in OTCD patients.
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The safety and feasibility of acupuncture as
supportive care treatment for children with
cancer has been reported previously, yet the
reasons for using acupuncture have not been a
specific focus of research.1–3 In this prospective
study, variables associated with acceptance of
acupuncture are investigated.
This study is currently ongoing at the
Integrative Therapies Program for Children with
Cancer at Columbia University Medical Center.
All acupuncture-naive patients were eligible for
inclusion. Upon enrollment, patients or parent/
guardian completed the Memorial Symptom
Assessment Scale (MSAS) every three weeks for
six months.4 Patients were offered treatment with
acupuncture or other integrative services each
time the MSAS was completed. If acupuncture
was accepted, a pre- and post-acupuncture
questionnaire was administered which included
information on reasons, expectations, and
satisfaction with acupuncture. MSAS scores,

physical symptom subscores, psychological
symptom subscores, and global distress indices
were calculated for each patient over the six
months.
Twenty-five patients (12M/13F) were
recruited. Patient diagnoses were leukemia/
lymphoma (15), brain tumor (4) and solid tumor
(6). Eight patients accepted acupuncture over
the six-month period (3M/5F; 32 percent).
Thirty-one acupuncture and 192 nonacupuncture treatments were administered.
The median number of days to acceptance of
acupuncture was 16 (Range 0–159). The median
number of acupuncture treatments per patient
was 2.5 (Range 1–11). Acupuncture acceptors
were older than non-acceptors (median 15.5
years vs. eight years, p=0.0005). The most
prevalent symptoms (>80 percent) in acupuncture
acceptors were cough, difficulty sleeping, pain,
nausea, headache, changes in taste, constipation,
and numbness/tingling. The most prevalent

FIGURE 1: Maximum MSAS Subscale Scores by Acupuncture Acceptance
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FIGURE 1: Although all

patients experienced similar
therapy-related symptoms,
children who accepted
accupuncture had hgher
scores on the Memorial
Symptom Assessment Scale,
including the Global Distress
Index, and Physical Symptom
subscales.
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* F or each subscore, the maximum score prior to acupuncture acceptance or maximum score over the total six months for
non-acceptors was used.
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symptoms (>80 percent) in non-acceptors were
pain, cough, nausea, hair loss, feelings of being
irritable, lack of appetite, vomiting, difficulty
sleeping, and lack of energy. Children who
accepted acupuncture reported slightly more
symptoms over the six-month period compared
to children who did not (Medianacu =11.7
vs. Mediannon-acu =8.6). When examining
maximum MSAS scores, which take into account
the frequency, severity, and distress of symptoms,
we found that patients who accepted acupuncture
had higher MSAS scores, physical symptom
subscores, and global distress indices compared
to non-acceptors (Figure 1). These differences
were not statistically significant. However, similar
trends for each subscale were seen when we
analyzed the average MSAS scores over the entire
study period.
Age is an important factor in acceptance of
acupuncture. Children who receive acupuncture
seem to report a similar constellation of
symptoms as children who do not receive
acupuncture. However, children who accept
acupuncture may experience these symptoms
at a greater frequency, increased severity, or at
heightened distress. Subsequent analyses with
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the entire study population will be necessary
to validate these initial findings. Evaluation
of variables related to the acceptance of
acupuncture, including therapy-associated side
effects and symptoms, may identify those patients
likely to benefit most from acupuncture services.

REFERENCES:
1.

REINDL TK, GEILEN W, HARTMANN R, WIEBELITZ KR, KAN G, WILHELM
I, ET AL. Acupuncture against chemotherapy-induced

nausea and vomiting in pediatric oncology. Interim
results of a multicenter crossover study. Supportive
Care in Cancer: Official Journal of the Multinational
Association of Supportive Care in Cancer. 2006.
14(2):172–6.
2.

A Retrospective Review Investigating the Feasibility
of Acupuncture as a Supportive Care Agent in a
Pediatric Oncology Service. Oral presentation at The
Society of Integrative Oncology Annual Meeting,
Nov. 11, 2006.

3.

Acupuncture is Feasible in Children with Cancer
with Low Platelet Counts, A Retrospective Review.
Oral presentation at The Society of Integrative
Oncology Annual Meeting, Nov. 16, 2007.

4.

COLLINS JC, BYRNES ME, DUNKEL IJ, LAPIN J, NADEL T, THALER HT, ET
AL. The measurement of symptoms in children with

cancer. Journal of Pain and Symptom Management.
2000. 19(5):363–377.

17

Disruption of Functional Anatomy in Listening and
Reading Comprehension Tasks in Childhood Epilepsy

Waleed Kurtom, M.S.II
Research Track
William D. Gaillard, M.D.,
Division Chief, Epilepsy and
Neurophysiology and
Director, Comprehensive
Pediatric Epilepsy Program,
Children’s National Medical
Center, Washington, DC.

Epilepsy populations often have greater atypical
language representation and often have (subtle)
impairments in language functions; thus we
aimed to look at connectivity beyond language
dominance. The actions of listening to and
reading stories show strong activation along the
superior temporal sulcus, and consistent left
laterality across ages in the inferior frontal gyrus,
middle frontal gyrus, and posterior temporal
regions. Cortical functional connectivity, as
indicated by the concurrent spontaneous activity
of spatially segregated regions, may determine
the reaction of the brain to external stimuli and
task requirements and appears altered in many
neurological and psychiatric disorders.2 Just et
al. (2004) found consistently lower functional
connectivity grouping autism when compared
to controls. This group’s findings suggest that
autism affects information integration and neural
processing.3

There were 59 healthy controls (4–12 yearolds) and 43 left focus localization-related epilepsy patients (4–12 year-olds) evaluated using
two fMRI language tasks (reading comprehension and listening comprehension) obtained at
3T with EPI BOLD techniques. fMRI maps
were interpreted at a standard threshold and laterality and connectivity data was gathered using
spm2. Healthy controls with frontal activation
have higher laterality in the middle frontal gyrus
(MFG) and inferior frontal gyrus (IFG) (p=.022,
p=.062) for the listening task. These controls also
have lower connectivity values in IFGR-IFGL
and MFGR-MFGL than patients without frontal
activation (p=.027, p=.062). When comparing
LI values between patients and healthy controls,
there are no differences in their laterality of
language in IFG and WA but there is a trend for
MFG variance between groups (patients n=43,
healthy controls n=59, p=.10). Patients for the
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FIGURE 2: Group

Activation Maps for our healthy
control group.

listening task show stronger connectivity values
than healthy controls in IFGR-IFGL, WALIFGL, MFGR-MFGL, and WAR-WAL (p<.01)
(Figure 1). In our patient population and healthy
control group, connectivity values did not vary
by age.
Patients for the reading task have more
atypical language representation in MFG and
WA than healthy controls (p=.015, p=.016) and
overall more atypical language representation in
all areas (p=.021). There were no connectivity
differences between healthy subjects and patients
in IFGR-IFGL, WAL-IFGL, and MFGRMFGL; for WAR-WAL, there are stronger
connectivity values in patients than in controls
(p<.001).
Our reading comprehension task was targeted to identify dominant middle temporal
gyrus and superior temporal gyrus in addition
to dominant IFG and MFG. Our listening task
was targeted to identify temporal receptive cortex
regions along the dominant superior temporal
sulcus.4 Further progression of this project will
include group activation maps created from our
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patients while they performed these tasks to see
if they have activation patterns consistent with
these studies’ findings; a comparison between
these group maps and the healthy control group
maps (Figure 2) would be of interest in establishing whether or not left-focus epilepsy affects
the strength of activation in these areas. Our
research has found that connectivity is similar
between patients and controls, with some modest
differences that may relate to working memory
issues. Our next step is to look at connectivity
differences between patients with typical and
atypical language representation.
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Pulmonary atypical carcinoid (AC) and typical
carcinoid (TC) tumors are in the bronchopulmonary neuroendocrine tumor (BPNET) classification that includes large-cell neuroendocrine
carcinoma (LCNEC), and small cell lung cancer
(SCLC).1 Previous small scale studies suggest
that resected pulmonary AC has a clinical presentation and survival pattern distinct from TC.
We reviewed a large epidemiologic cancer database, and hypothesized: 1) resected pulmonary
TC will show a favorable clinical presentation
and survival pattern, 2) resected AC will show a
clinical presentation and survival pattern similar
to LCNEC and 3) resected SCLC will demonstrate the least favorable clinical presentation and
survival pattern.

FIGURE 1
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The Surveillance Epidemiology and End
Result database was queried to compare demographic (age, gender, ethnicity) and tumor
specific clinical variables (including nodal status
and stage) in 2239 patients diagnosed with, and
undergoing lobectomy for TC, 145 patents with
AC, 510 patients with LCNEC and 1521 patients
with SCLC from 2001 to 2006. We performed
univariate analysis of clinical variables and
analysis of survival among the BPNET histologic
types.
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AC patients presented at a similar age of diagnosis (Mean 59.9 years) as TC patients (Mean
age 58.5) but younger than LCNE and SCLC
patients (Mean age of 65.3 and 66.2 respectively,
P < 0.001). AC and TC had higher predilection towards female patients (70.3 percent and
68.7 percent) than LCNE and SCLC (45.7
percent and 51.4 percent, p < 0.001). All BPNET
patients had a statistically equal predilection to
white ethnicity. AC patients had greater incidence of histologically positive lymph nodes and
higher pathologic stage compared to TC, similar
to LNEC but more favorable than SCLC (p <
0.001). Survival analysis showed a step wise mean
survival of 40.0 ± 1.9 months for SCLC, 46.2 ±
2.2 months for LCNEC, 58.3 ± 2.5 months for
AC tumors,
and 70.2 ± 0.2
months for
TC = Typical carcinoid tumor
TC tumors.
TC
AC = Atypical carcinoid tumor
TC patients
LNEC = Large-cell
AC
neuroendocrine
demonstrated
carcinoma
favorable
SCLC = Small cell
lung cancer
survival and
LNEC
SCLC patients
SCLC
poorer survival compared to AC
!
and LNEC
patients
80
(Figure 1).
TC and
SCLC tumors
are histologies
that exhibit clinical behavior distinct from AC
and LCNEC. Atypical carcinoid tumors should
be staged and treated with stage appropriate
neoadjuvant and adjuvant therapeutic strategies
similar to LCNE and other non-small cell lung
cancers.
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Identification of Aspirin Resistant Biomarkers
Using Whole Blood Genome Profiling
Cardiovascular disease (CVD) is the leading
fold change (FC ≥1.8, 2.0), were calculated and
cause of death in the industrial world, where
then considered for further analysis and assays
one in three adults are diagnosed with CVD.1
using Pathway Studio 6.1 and Ingenuity Pathway
Acute coronary syndromes alone account for
Analysis (IPA).
30 percent of all deaths in the U.S. each year.2
The gene expression profile indicated that
Atherosclerotic plaque formation and rupture
284 genes (p ≤ 0.05, FC ≥ 1.8) were differentially
accounts for the majority of acute coronary
expressed, of which 61 genes were strongly differsyndromes, as these trigger platelet aggregation
entially expressed (FC ≥ 2.0). Notably, pathway
leading to arterial occlusion. The most comanalysis (Figure 1) revealed that prostaglandin
monly prescribed inhibitor of platelet aggregaE synthase (PGES, FC= +3.62) and thrombostion is acetylsalicylic acid, commonly known
pondin-1 (THBS1, FC = -2.17) are closely related
as aspirin. The effectiveness of aspirin has been
to cell adhesion.
questioned in past years. Clinical studies revealed
In search of potential biomarkers for AR,
that as many as 20 percent of patients taking
gene expression profiling of AR patients revealed
aspirin have recurrent ischemic vascular events,
that PGES is significantly upregulated. PGES
suggesting that aspirin may be ineffective for
synthesizes PGE2, a metabolite downstream of
some people. These clinical findings inspired
COX that causes both pro- and anti-coagulation
the term aspirin resistance (AR). The underlying
effects downstream upon release from activated
causes of AR are unknown, and few clinical
platelets as a function of its concentration.
studies attempt to describe them. Some attribute
Membrane-bound PGES synthesizes PGE2
AR to an inadequate dosage of aspirin, patient
from [PG]H2 derived from COX-1 and a related
non-compliance, difference in absorption, or
enzyme, COX-2.4 The COX-2/PGES pathway is
genetic causes.3 Our research study attempts
resistant to aspirin and could represent an alterto identify possible biomarkers, which could
native route to blood coagulation.
be used to diagnose patients as AR via genetic
profiling.
ASPIRIN
Continued on p. 22
Aspirin resistance is measured using the
Verifynow ® System.
Patients with 550
FIGURE 1: Functional relationships of differentially
Aspirin Reaction Units
expressed genes in AR patients and known contributors of
(ARU) or more are
cell adhesion.
considered AR, while
patients below 550
CNR1 = Cannabinoid Receptor-1,
ARU are considered
ICAM1 = Intercellular
aspirin-sensitive. Gene
Adhesion Molecule-1,
expression profiling
ITGAM = Integrin Alpha-M,
was conducted on
PECAM1 = Platelet/
eight aspirin-sensitive
endothelial cell
(424 ARU ± 37 σ)
adhesion molecule 1,
and eight resistant
PTGES = prostaglandin E
patients (568 ARU
± 15.4 σ) via the
synthase, SPP1 = secreted
Affymetrix HG-U133
phosphoprotein-1,
2.0 GeneChip arrays.
THBS1 = thrombospondin-1,
Using GeneSpring
VCAM1 = vascular cell adhesion
10.0, genes satisfying
molecule-1, VWF = von Willebrand factor.
two parameters,
P-value (≤ 0.05) and
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Another potential biomarker of interest is
THBS1 due to its close functional relationship
with von Willibrand Factor (vWF). vWF is
a multimeric protein that promotes adhesion
of platelets to sites of vascular injury. THBS1
inhibits blood coagulation by decreasing vWF
multimer size.5 Our gene expression profile
indicates that THBS1 is significantly downregulated, which suggests that vWF has a higher
hemostatic competence in AR patients.
Patients resistant to aspirin remain unknowingly at risk for sudden cardiovascular events.
Our gene expression profiling identified several
promising pathways that could explain the
aspirin resistance phenotype. Further investigation will be required to determine the contribution of these pathways to aspirin resistance.
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The maintenance of muscle mass is regulated by
a balance between protein synthesis and protein
degradation pathways; a balance shifted toward
protein degradation during atrophy. Muscle
atrophy occurs as a consequence of various
conditions, such as aging, bed rest, cancer,
denervation, injury, and joint immobilization.
The increased proteolysis in atrophying muscles
results from the activation of the ATP-dependent
ubiquitin proteasome proteolysis pathway.
Atrogin-1 is an ubiquitin-protein ligase (E3)
that is a critical component of the ubiquitinproteasome pathway (Figure 1), expressed
specifically in striated (cardiac and skeletal)
muscle. It directs the breakdown of muscle
protein in response to various conditions (ex.
disuse, cancer, starvation), and it is downregulated during the hypertrophy response.
As a result, Atrogin-1 has strong potential as a
modifier of muscle size and strength. Examining
genetic variation in the Atrogin-1 gene may help
explain inter-individual differences in muscle
size and strength, as well as differences in the
response to resistance training.
Seven hundred fifty-eight Caucasian collegeaged subjects (446 females; 312 males; age 24 ± 8
y) participated in a 12 week supervised strength

training program for the upper arm muscles
(biceps and triceps). The program consisted
of two 45–60 minute sessions per week for 12
weeks, as each session was supervised by an
exercise physiologist professional or a trained
student. Muscle size (via MRI) and strength
measurements (1 RM and isometric) were taken
before and after training. The study participants
were then genotyped for five Atrogin-1
Single Nucleotide Polymorphisms (SNPs);
rs4871385, rs6990663, rs3739287, rs2891779,
and rs16898553. A list of the SNPs that were
genotyped and their positions in the Atrogin-1
gene can be found in Table 1. Genotyping for
the Atrogin-1 SNPs was performed using the
TaqMan allele discrimination assay. Associations
between the SNP and each phenotype were
tested using ANCOVA with Sidak post-hoc tests.
Significant associations between Atrogin-1
SNPs and several muscle phenotypes were
found. The most significant results were found
in females with the rs2891779 SNP, which is
located in the promoter region of the Atrogin-1
gene. Specifically, when a dominant model was
applied, females having one or two copies of
the A allele had significantly higher baseline
isometric strength, torque, and muscle quality
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FIGURE 1: Atrophy and Hypertrophy pathways
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Based on Hoffman EP, Nader GA. Nat Med. 2004;10(6):584–5.
2.
than those who were homozygous for the G
allele. These same associations were seen in both
the dominant and non-dominant arms.
This data suggests that the Atrogin-1
rs2891779 SNP influences baseline muscle
3.
strength, torque, and muscle quality in females,
which may indicate a sexspecific effect for this SNP.
Gene
GeneID
The location of this SNP
Atrogin-1
114907
in the promoter region of
Atrogin-1
114907
Atrogin-1 suggests that
Atrogin-1
114907
it may exert its influence
through regulation of
Atrogin-1
114907
Atrogin-1 expression. This
Atrogin-1
114907
data contributes additional
insight to the complex
genetic milieu that affects muscle size and
strength.
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RefSeq

Position on MRNA

rs4871385
rs6990663
rs3739287
rs2891779
rs16898553

NM_05229.2
NM_058229.2
NM_058229.2
NM_058229.2
NM_058229.2

225 (Synonymous cds)
-11,757 upstream of mRNA
798 (Synonymous cds)
-2,387 upstream of mRNA
-2,560 upstream of mRNA

MAFbx mediated MyoD proteolysis prevents skeletal
muscle atrophy in vivo. PLoS ONE. 2009;4(3):4973.

TABLE 1: Single Nucleotide
Polymorphisms and their
positions in Atrogin-1.

polymorphisms associated with human muscle
size and strength. Med Sci Sports Exerc. 2004;
36(7):1132–1139.
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The purpose of this study was to examine
whether AKT2 Single Nucleotide Polymorphisms
(SNPs), were associated with muscle strength and
size phenotypes and responsiveness to resistance
training in men and women. The gene variants tested were: rs2304186 (3’ UTR regulatory
region), rs969531 (5’ UTR regulatory region),
and rs892118 (intronic region).
The AKT serine/threonine kinase is involved
in various important cellular events such as cell
survival, proliferation and differentiation, as
well as insulin-stimulated glucose metabolism
and cellular protein synthesis.1,2 Activation
of AKT is essential for cell survival during
myogenesis, and consequently AKT activity
increases during myogenesis.3 Several studies
have demonstrated that expression of the AKT2
isoform in particular is significantly elevated
during skeletal muscle differentiation.2,4,5,6
Since AKT2 is activated by exercise and muscle
contraction in both rodents and humans, it is an
attractive target gene for studying human skeletal

muscle size and function pre- and post-resistance
training.7
In this prospective genome-wide association
study, 753 Caucasian subjects (449 female, 304
male) [from the FAMUSS cohort] were enrolled
in a resistance-training program. The phenotypes
being measured included muscle strength and
muscle and fat volume. All phenotype measures
were examined before and after a 12-week
training program. For each SNP, a Chi-square
analysis was used to test Hardy-Weinberg equilibrium. Associations between each SNP and phenotype measure were tested with Sidak post-hoc
tests. Each model included baseline body weight
and age as covariates and used a dominant genetic
model.
We found that the AKT2 rs2304186 variant
was significantly associated with baseline subcutaneous fat in males only (Table 2). Males with a
copy of the T allele demonstrated a significantly

AKT2 VARIANTS

Continued on p. 25

TABLE 1. ANALYSIS OF AKT2 SNPS WITH 1-RM STRENGTH, ISOMETRIC
STRENGTH AND WHOLE MUSCLE VOLUME IN FMS CAUCASIANS:
Phenotype
Gender
			
Baseline 1-RM strength
Difference in 1-RM strength
% change in 1-RM strength
Baseline isometric strength
Difference in isometric strength
% change in isometric strength
Baseline whole muscle volume
Difference in whole muscle volume
Baseline 1-RM strength
Difference in 1-RM strength
% change in 1-RM strength
Baseline isometric strength
Difference in isometric strength
% change in isometric strength
Baseline whole muscle volume
Difference in whole muscle volume

Female
Female
Female
Female
Female
Female
Female
Female
Male
Male
Male
Male
Male
Male
Male
Male

AKT2
(rs7254617)

AKT2
(rs892118)

AKT2
(rs2304186)

AKT2
(rs969531)

1.02; NS
2.18; NS
2.11; NS
0.45; NS
0.11; NS
0.22; NS
1.32; NS
0.31; NS
0.24; NS
0.11; NS
0.36; NS
0.28; NS
0.48; NS
0.09; NS
1.90; NS
1.43; NS

1.62; NS
1.66; NS
2.38; NS
1.23; NS
0.51; NS
0.52; NS
0.61; NS
0.21; NS
0.09; NS
0.12; NS
0.52; NS
0.07; NS
0.15; NS
0.15; NS
0.33; NS
3.43; 0.0345

0.46; NS
0.42; NS
1.16; NS
0.27; NS
0.36; NS
0.13; NS
0.54; NS
0.20; NS
5.17; 0.0062
4.20; 0.0160
6.87; 0.0012
0.10; NS
3.38; 0.0353
1.69; NS
0.98; NS
3.23; 0.0418

0.07; NS
0.43; NS
1.01; NS
0.16; NS
5.33; 0.0051
3.95; 0.0198
0.69; NS
0.24; NS
0.28; NS
0.46; NS
0.14; NS
0.52; NS
0.57; NS
0.46; NS
0.31; NS
0.49; NS

* All models adjusted for age & baseline body mass
** Significance level is 0.0062 after correction for multiple testing.
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AKT2 VARIANTS
Continued from p. 24

TABLE 2. SIGNIFICANT ASSOCIATIONS:
SNP

Phenotype

greater mean baseline
subcutaneous fat
AKT2
Difference in
volume (p=0.0243)
(rs892118)
whole
muscle
than males that were
volume
homozygous for the
AKT2
Baseline
G allele (Table 1). No
(rs2304186)
1-RM
strength
significant difference
in strength or volume
was found in females.
AKT2
Difference in
The AKT2
(rs2304186) 1-RM strength
rs969531 variant
was significantly
AKT2
% change in
associated with dif(rs2304186) 1-RM strength
ference in isometric
strength (p=0.0212)
AKT2
Difference in
and the percent
(rs2304186) isometric strength
change in isometric
strength (p=0.0288)
AKT2
Difference in
in females, but not
(rs2304186)
whole
muscle
in males (Table 2).
volume
Females who had a
AKT2
Difference in
copy of the G allele
(rs969531)
isometric strength
demonstrated a
significantly greater
percent change in
AKT2
% change in
isometric strength
(rs969531)
isometric strength
than females that
were homozygous for
the A allele (Table 1).
The AKT2 rs892118 variant was shown to
3.
be significantly associated with the difference in
whole muscle volume (p=0.0098) and subcutaneous fat volume (p=0.0187) in males (Table 2).
These data suggest that AKT2 genotypes have
4.
a sex-specific effect on baseline values of fat in the
human arm. Further, AKT2 gene variants play
a significant role in increases in muscle strength
5.
and size. Further applications of this study will
include testing other data sets with similar phenotypes as well as complete functional studies of
these AKT2 SNP’s in skeletal muscle cells.
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Gender

F-test

P-value

N; adjusted mean ± SEM

P-value for
significantly
different means

Male

3.43

0.0345

CC (N=117; 70634 ± 4053)
CT (N=52; 86995 ± 6083)
TT (N=8; 97639 ± 15501)

NONE

Male

5.17

0.0062

GG (N=112; 27.66 ± 0.54)
GT (N=141; 26.43 ± 0.48)*
TT (N=67; 29.13 ± 0.70)*

*p=0.0051

Male

4.20

0.0160

GG (N=104; 10.14 ± 0.48)
GT (N=124; 10.97 ± 0.44)*
TT (N=60; 8.72 ± 0.64)*

*p=0.0122

Male

6.87

0.0012

GG (N=104; 38.80 ± 2.03)
GT (N=124; 44.11 ± 1.85)*
TT (N=60; 32.14 ± 2.68)*

*p=0.0009

Male

3.38

0.0353

GG (N=103; 19.69 ± 2.02)
GT (N=123; 26.06 ± 1.85)
TT (N=60; 19.62 ± 2.66)

NONE

Male

3.32

0.0418

GG (N=63; 81718 ± 5505)*
GT (N=81; 78605 ± 4857)
TT (N=37; 59775 ± 7185)*

*p=0.0481

Female

5.33

0.0051

GG (N=211; 12.31 ± 0.94)*
GA (N=208; 14.58 ± 0.95)
AA (N=34; 20.26 ± 2.35)*

*p=0.0054

Female

3.95

0.0198

GG (N=211; 21.90 ± 1.71)*
GA (N=208; 25.90 ± 1.73)
AA (N=34; 34.04 ± 4.28)*

*p=0.0256
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An essential part of medical education is the use
of evidence-based medicine. In April 2009, I
participated in a medical mission to Egypt with
Hands Along the Nile Development Services
(HANDS), facilitated by local partner organization Coptic Evangelical Organization for Social
Services (CEOSS), where we held three workshops on navigating through the PubMed MeSH
database for 35 physicians in El Minia and Cairo.
PubMed was chosen due to its reliability, accessibility, and because it is free of charge. In previous
missions, Egyptian physicians voiced a need for
internet training, however their level of experience with internet search engines was unclear.
Therefore, we decided that this would be an
appropriate time to conduct a needs assessment.
During each session we administered a pre-test
consisting of 15 questions and a post-test consisting of 11 questions to help assess the relevance
of our presentation to the physicians. There were,
however, limitations of the data collected from

the pre- and post-tests, including small sample
size, late-comers resulting in more post-test than
pre-test responders, and possible misinterpretation
of the questions which may explain discrepancy
in the data (for example, only 5 of 25 responders
stated that they have heard of PubMed, while 7
of 25 stated they had used the database at least
weekly).
Each session began with a power-point presentation providing a step-by-step approach to
navigating the MeSH database. The remainder of
the session involved the participants formulating
several questions, using the PICO format, which
were then used to search for evidence-based literature through MeSH. PICO is a way of focusing
and individualizing a clinical question in order
to facilitate a search for relevant evidence-based
information. The structure includes:
1.	“P” for patient information/characteristics or problem;
2.	“I” for interventions, exposures or factors

GRAPH 1: How often do you use internet resources in your practice? How often do you use the PubMed search engine?
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that may influence a
GRAPH 2: How much training have you had in using internet resources (in general)? How many hours of training have
prognosis;
you received in using PubMed?
3.	“C” for comparison if
applicable; and
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scoring.
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collected from the pre-test,
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PubMed [Graph 2], while
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2
for medically-relevant
information [Graph 1].
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Although 8 of 20 (40 permedical
cent) pre-test responders
curriculum
felt very comfortable in
Amount of Time
using PubMed, none felt
comfortable enough to
throughout the session as the physicians grew
train others [Graph 4].
more involved and with many eagerly volunBy the end of the session, the comfort levels
teering to lead different search inquiries. One
were increased with 20 of 34 (59%) post-test
doctor indicated that “before I depended on my
responders indicating that they felt “very comkids to show me how to deal with the net, but
fortable” using MeSH, and with 4 of 34 indinow I can [do it on my own].”
cating that they were now “comfortable enough
to train others” in the use of PubMed [Graph
4]. Their increasing comfort was also apparent
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GRAPH 3: Can you define Evidence-Based Medicine?
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Although the main objective of this presentation was to provide training, we were pleased to
find that the physicians were extremely receptive to the material, and that many had taken
on a leadership role during the sessions. Some
physicians were now able to help their colleagues

navigate through the search engine without need
for any further assistance. Having resources, other
than google, to search for evidence-based literature will allow these doctors to not only update
their practices, but will also promote the utilization of evidence-based medicine as they continue
to pass this information on to their colleagues.
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Historically, physicians have been involved with
injury prevention, such as car safety devices and
smoking cessation. Homicide due to firearm
injury is the second leading cause of death in
the 10–24 age group.1 In fact, homicide of a
household member is three times more likely and
suicide risk increases by five times in homes with
guns than in homes without guns.2 Medical societies, such as the American College of Physicians,
the American Academy of Pediatricians, and the
American Medical Society all support the safe
storage of guns.3
Out of all health care providers in the United
States, pediatricians have the most access to parents.1 Barkin et al. states that, “because families
must bring their children in for routine medical
examinations before the children can attend first
grade, health professionals have a unique opportunity for early intervention before gun injury,
unintentional or intentional, manifests itself.”4
Naureckas et al. found that 25 percent of children between the ages of three and four could
pull a trigger of a gun.5 Jackman et al. found that

76 percent of boys who encounter a gun in a safe
environment would handle the gun and 48 percent would pull the trigger.6 Due to the high risk
of mortality from gun violence in children and
the decimating impact that death has on loved
ones, physicians can play vital roles in health
prevention and gun safety.
While most pediatricians believe it is important to counsel patients about gun safety, less
than half of them do.4 There are many surmountable barriers to firearm safety counseling,
such as a lack of awareness and prioritization
of the issue, insufficient physician knowledge
or training, low confidence in the effectiveness
counseling, and physician time constraints.
Barkin et al. found that “significant positive associations [with firearm safety counseling include]
younger clinician age, female sex, household
handgun ownership status, and the perception
that firearm safety counseling is beneficial.”4
Likewise, Cheng et al. found that “the primary
predictors of physician counseling [are] an issue’s
importance, a physician’s perceived self-efficacy,
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and perceived effectiveness of counseling, while
concerns about time and reimbursement were
secondary.”7 Residents [are] more likely to discuss injury prevention and less likely to perceive
a barrier if their attending physicians placed
importance on this issue.8 Most patients agree
that physicians can influence public opinion, but
much fewer think that physicians are knowledgeable in gun safety counseling.9,10 Even though
physicians cite several barriers to injury prevention counseling, patients have confidence in
physicians’ abilities to change public opinion and
consequently, these obstacles can be overcome
with the following proposed solutions.11
Recommendations for decreasing unintentional injury and death due to guns can be
prevented with physician involvement in firearm
safety counseling. Cheng et al. stated that “preventive medicine training at all levels, which
improves counseling skills and self-efficacy, [is]
needed for physicians to attempt counseling and
gain experience and confidence.”7 First, increased
physician education and exposure to injury prevention training throughout medical school and
residency may reinforce the importance of this
issue and thus remove several barriers to firearm
safety counseling. Second, primary care and
pediatric residency programs can teach residents
basic information about gun safety and how
to research educational information for their
patients. Third, physicians can also promote gun
safety non-verbally by placing informative brochures in waiting rooms and including questions
about gun ownership, exposure, and storage on
patient intake forms filled out at each office visit.
Everett et al. stated that “interventions aimed at
increasing general health promotion activities by
physicians [are] successful in increasing physician
counseling and [result] in positive changes in
their patients’ health behaviors…and psychological health.”11 By coupling physician training
with patient education, positive public health
implications can be achieved.
Previous literature has stated that “the status
of physicians’ perceptions regarding their ability
to impact patients regarding firearm safety is
where physicians’ perceptions of counseling
patients regarding smoking were 25 years ago.
The growing crisis in firearm related morbidity and mortality cannot wait another 25
years before the clinical community becomes
involved as change agents.”11 Not too long ago,
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physicians also championed the use of seat belts
in cars, thereby decreasing motor vehicle mortalities. Their role as advocates of gun safety is
an example of another important public health
reform issue with great potential for positive
results, which should be addressed now in the
midst of our ongoing health care reform.
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